Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LIMN · NASDAQ · Biological Products, (No Diagnostic Substances)
$2.51−0.30 (−10.68%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Liminatus Pharma (LIMN) · oqro.io/stocks/LIMN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No fund moves found
Nothing has been reported for this company in this source yet.
No fund reported this stock
No mutual fund or ETF listed it in its latest public N-PORT report. Funds report each quarter, about two months after the quarter ends.
None of the 31 ETFs OQRO follows reported LIMN in its latest N-PORT report.
Source: each ETF’s latest SEC Form N-PORT report. Vanguard ETFs are share classes of larger funds, so their figures are the whole fund’s.